Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

People with alopecia areata often have lower vitamin D levels than healthy people.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.

Rituximab can cause skin issues, but baricitinib may help improve them.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Oral Apremilast effectively treats alopecia areata in most patients.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.

Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.